ADAR1 Capital Management Discloses 9.9% Stake in Grace Therapeutics, Inc.

ADAR1 Capital Management, LLC, along with its affiliates ADAR1 Capital Management GP, LLC and Daniel Schneeberger, filed a Schedule 13G/A on May 15, 2026, regarding their holdings in Grace Therapeutics, Inc. (GRCE). The filing reports a beneficial ownership of 1,717,426 shares of common stock, representing a 9.9% ownership stake in the company. This position primarily consists of shares underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. The reporting persons have noted that an additional 412,288 shares underlying warrants were excluded from the total due to a 9.99% beneficial ownership limitation clause. Daniel Schneeberger serves as the manager for the entities and is a control person for the investment adviser. The filing indicates that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This filing represents an increase from a previously reported 0% position.